We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

487 hedge funds and large institutions have $11.6B invested in Royalty Pharma in 2025 Q3 according to their latest regulatory filings, with 92 funds opening new positions, 206 increasing their positions, 131 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

440% more call options, than puts

Call options by funds: $50.3M | Put options by funds: $9.31M

74% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 53

67% more funds holding in top 10

Funds holding in top 10: 6 → 10 (+4)

57% more repeat investments, than reductions

Existing positions increased: 206 | Existing positions reduced: 131

7% more funds holding

Funds holding: 455 → 487 (+32)

5.29% less ownership

Funds ownership: 81.34% → 76.05% (-5.3%)

6% less capital invested

Capital invested by funds: $12.4B → $11.6B (-$760M)

Holders
487
Holders Change
+32
Holders Change %
+7.03%
% of All Funds
6.39%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
92
Increased
206
Reduced
131
Closed
53
Calls
$50.3M
Puts
$9.31M
Net Calls
+$41M
Net Calls Change
-$22.7M

Top Buyers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$216M
2
Capital International Investors
Capital International Investors
California
+$193M
3
Jane Street
Jane Street
New York
+$86.6M
4
DAM
Dorsey Asset Management
Illinois
+$85.1M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$79.1M

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$921M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$448M
3
Viking Global Investors
Viking Global Investors
Connecticut
-$93.6M
4
JAM
Jupiter Asset Management
United Kingdom
-$89M
5
Morgan Stanley
Morgan Stanley
New York
-$88.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
WANY
451
Wealthspire Advisors (New York)
New York
$3.04K +$3.11K +86 New
BTI
452
Blue Trust Inc
Georgia
$3.04K +$1.23K +34 +65%
ABWM
453
Alpine Bank Wealth Management
Colorado
$2.89K – – –
RFP
454
Root Financial Partners
California
$2.82K +$2.9K +80 New
EP
455
Essential Partners
California
$2.75K – – –
CH
456
Cromwell Holdings
Wyoming
$2.33K – – –
EWP
457
Elevation Wealth Partners
California
$2.26K +$2.32K +64 New
CI
458
CX Institutional
Indiana
$2K – – –
NL
459
NVWM LLC
Pennsylvania
$1.84K – – –
KG
460
Kilter Group
New York
$1.76K – – –
TPCW
461
TD Private Client Wealth
New York
$1.73K +$434 +12 +32%
TIM
462
Tortoise Investment Management
New York
$1.59K +$1.09K +30 +200%
W
463
WealthCollab
Washington
$1.59K +$1.63K +45 New
CA
464
Clearstead Advisors
Ohio
$1.41K +$1.34K +37 +1,233%
GWM
465
Geneos Wealth Management
Colorado
$1.38K -$12.3K -340 -90%
PWA
466
Principia Wealth Advisory
Texas
$1.2K -$72 -2 -6%
JFGIW
467
Johnson Financial Group Inc (Wisconsin)
Wisconsin
$1.06K +$1.09K +30 New
PMAM
468
Picton Mahoney Asset Management
Ontario, Canada
$1K – – –
ETS
469
ESL Trust Services
New York
$988 +$1.01K +28 New
BI
470
Binnacle Investments
Iowa
$847 +$869 +24 New
Kayne Anderson Rudnick Investment Management
471
Kayne Anderson Rudnick Investment Management
California
$777 -$4.31K -119 -84%
RIL
472
Rothschild Investment LLC
Illinois
$741 +$615 +17 +425%
WA
473
WPG Advisers
Maryland
$706 – – –
AF
474
Advisornet Financial
Minnesota
$670 – – –
TFM
475
TFC Financial Management
Massachusetts
$565 – – –
17 18
19
20 21

RPRX Hedge Fund Activity: Q3 2025 in Review

487 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q3 2025, worth a combined $11.6B — down 6.2% from $12.4B a quarter earlier.

Buyers outnumbered sellers: 92 funds opened new RPRX positions and 53 closed out — a net gain of 39 holders — while 206 added to existing stakes and 131 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $216M. The largest seller was Vanguard Group, cutting an estimated $921M.

  • 487 institutional investors held Royalty Pharma (RPRX) as of Q3 2025, up from 455 in Q2 2025.
  • Funds reported $11.6B of Royalty Pharma stock for Q3 2025, down 6.2% quarter-over-quarter.
  • 92 funds opened new Royalty Pharma positions in Q3 2025 and 53 closed out, a net change of +39 holders.
  • The largest Royalty Pharma buyer in Q3 2025 was Adage Capital Partners, an estimated $216M added.
  • The largest Royalty Pharma seller in Q3 2025 was Vanguard Group, an estimated $921M sold.

Based on aggregated 13F filings for Q3 2025.